Enovis (ENOV) – Investment Analysts’ Recent Ratings Updates

Enovis (NYSE: ENOV) has recently received a number of price target changes and ratings updates:

• 8/8/2026 – Enovis was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/7/2026 – Enovis had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $30.00 price target on the stock.
• 8/7/2026 – Enovis had its price target lowered by Wells Fargo & Company from $40.00 to $39.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – Enovis had its price target raised by BTIG Research from $39.00 to $40.00. They now have a “buy” rating on the stock.
• 7/29/2026 – Enovis was upgraded by Zacks Research from “strong sell” to “hold”.
• 7/28/2026 – Enovis had its “buy” rating reaffirmed by UBS Group AG. They now have a $51.00 price target on the stock, up from $50.00.
• 7/28/2026 – Enovis had its “buy” rating reaffirmed by UBS Group AG. They now have a $51.00 price target on the stock, up from $50.00.
• 7/21/2026 – Enovis was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/8/2026 – Enovis is now covered by BMO Capital Markets. They set an “outperform” rating and a $29.00 price target on the stock.
• 7/8/2026 – Enovis had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 7/8/2026 – Enovis was upgraded by BMO Capital Markets to “strong-buy”.
• 7/6/2026 – Enovis was given a new $32.00 price target by Evercore Inc.
• 7/6/2026 – Enovis was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/30/2026 – Enovis was downgraded by Zacks Research from “hold” to “strong sell”.
• 6/28/2026 – Enovis was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/20/2026 – Enovis was upgraded by Wall Street Zen from “hold” to “buy”.

Insider Activity at Enovis

In related news, insider Oliver Engert acquired 1,200 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was purchased at an average cost of $21.62 per share, with a total value of $25,944.00. Following the transaction, the insider directly owned 51,840 shares of the company’s stock, valued at $1,120,780.80. This trade represents a 2.37% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have purchased 4,200 shares of company stock valued at $92,084. Company insiders own 2.90% of the company’s stock.

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.